NRC-2694 is an epidermal growth factor receptor ( EGFR ) antagonist with anti-cancer and anti-proliferative properties. In Vitro NRC-2694 at 80 ng (190 nm) concentrations causes comparable inhibition of EGFR expression. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo In toxicity studies, the maximum tolerated dose of NRC-2694 in male and female mice is 2000 mg/kg (po). NRC-2694 (10 mg/kg) regresses the tumor in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:EGFR